Company profile: Tocris Bioscience
1.1 - Company Overview
Company description
- Provider of reagents for non-clinical life science research, including TR-FRET donors (CoraFluor 2) for assay development and biomolecule labeling; selective HDAC3 degraders (JPS036) for targeted protein degradation; M5 receptor antagonists (VU 6019650); dual LAG3 interaction inhibitors (SA-15-P) for immune checkpoint research; ALDH detection substrates (BAAA-DA); and near-infrared fluorogens (SiRA 2) for RNA imaging.
Products and services
- ALDH Detection Reagent - BAAA-DA: A fluorescent substrate of ALDH enabling identification of cells with high ALDH activity by flow cytometry and FACS
- CoraFluor™ 2, amine reactive: A terbium-based TR-FRET donor for assay development, labeling antibodies, proteins, and peptides to enable time-resolved energy transfer assays
- JPS036: A selective PROTAC® HDAC3 degrader used in targeted protein degradation research for non-clinical life science studies
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Tocris Bioscience
Rancho BioSciences
HQ: United States
Website
- Description: Provider of fee-for-service life science data curation and knowledge management, leveraging open-source tools and public domain data for Pharma, non-profit foundations, and academia. Services include data curation, data governance and models, bioinformatics analysis (including genetic variant annotation), workflows and pipelines, knowledge mining, and creation of target profiles to support research and development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rancho BioSciences company profile →
IMGM Laboratories
HQ: Germany
Website
- Description: Provider of advanced genomic services via a service center in Martinsried, Germany for academic and industrial genome research, serving pharma, diagnostics, academia and biotech. Accredited to DIN EN ISO/IEC 17025 for gene expression analysis using Agilent microarrays and qPCR, and offering first-class NGS, metagenomic sequencing, biomarker discovery, pharmacogenetics, and qPCR/ddPCR-based biodistribution studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IMGM Laboratories company profile →
NAT Diagnostics
HQ: United States
Website
- Description: Provider of a molecular diagnostic platform for true point-of-care infectious disease testing in physician offices, clinics, pharmacies, and other sites where patients are seen by medical personnel, delivering highly accurate results to improve the diagnostic experience.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NAT Diagnostics company profile →
Genomic Vision
HQ: France
Website
- Description: Provider of novel genetic tests and research tools for life sciences, developed and commercialized using Molecular Combing, a proprietary single DNA molecule detection technology, combined with biomarker discovery; focused on DNA analysis and genetic testing in cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genomic Vision company profile →
GenMark Diagnostics
HQ: United States
Website
- Description: Provider of molecular diagnostics leveraging electrochemical sensor detection to identify up to 72 biomarkers in a single sample. Offers the XT-8 System with FDA 510(k) clearance, the cobas eplex system for automated multiplexed nucleic acid testing via single-use cartridges, and the cobas 4800 System for automated sample prep and real-time PCR supporting sexual health, microbiology, oncology, and genomics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GenMark Diagnostics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Tocris Bioscience
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Tocris Bioscience
2.2 - Growth funds investing in similar companies to Tocris Bioscience
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Tocris Bioscience
4.2 - Public trading comparable groups for Tocris Bioscience
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →